Available Technologies

No technologies match these criteria.
Schedule UC TechAlerts to receive an email when technologies are published that match this search. Click on the Save Search link above

Find technologies available for licensing from UCSF.

4D-seq: Single Cell RNA-sequencing with in situ Spatiotemporal Information

To develop a novel imaging-based single cell RNA-sequencing (scRNA-Seq) platform that allows capturing of spatiotemporal information and cellular behavior of the sequenced cells within tissue.

Covalent Activators Of K2p Channels

Researchers at UCSF have developed a series of small-molecules that selectively label the TREK1 (KCNK2) potassium ion channel. These compounds are the first covalent activator of any member of the K2P family of potassium ion channels.

Novel CRISPR Gene Therapy for Haploinsufficiency

This technology presents a way to treat human genetic disease caused by haploinsufficiency and reduced protein production. The method employs the use of adeno-associated viral (AAV) vectors for the in vivo delivery of a CRISPR-based gene expression activator (CRISPRa) that boosts transcription from the existing functional copy of the affected gene.

Small Molecule Activated Switches for Regulating Cell Therapies Small Molecule

This novel technology enables refined temporal control of protein-protein interactions that can be used to regulate cell therapies, including CAR T-cells and “cell factories”.

Novel Synthesis of Streptogramin A Antibiotics

A modular, scalable, chemical synthesis platform that produces new Streptogramin A class antibiotic candidates.

Prospective Isolation Of Tumor-Reactive Cytotoxic CD4+ T Cells For Bladder Cancer Therapy

UCSF researchers have discovered a method for the isolation and expansion ex vivo of an endogenous population of bladder tumor-reactive cytotoxic CD4+ T cells that can be used to specifically and potently treat bladder cancer.

Modulating IRE1a/ß Kinase for Treatment of Unfolded Protein Response (UPR)-related Diseases

This invention identifies a series of compounds which can selectively regulate the kinase activity of IRE1α and IRE1β, which are paralogous enzymes critical for the activation of the unfolded protein response (UPR) and that may have implications in cell-degenerative diseases such as diabetes, cancer, fibrosis, asthma, and retinitis pigmentosa.  

First-in-class Targeted Therapy for Acute Kidney Injury (AKI)

This invention provides the first-in-class targeted therapy for acute kidney injury (AKI) by systemically administering protein WFDC2.